^
Association details:
| Biomarker: | ERBB3 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | patritumab deruxtecan (U3-1402) (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
/ 26 - HER3-targeting antibody-drug conjugate, U3-1402, induces tumor regression in a variety of xenograft models and exerts enhanced antitumor activity by combining with PI3K inhibition
Published date:
05/15/2020
Excerpt:
Antitumor activity of U3-1402 was assessed in various xenograft models of human cancers, including breast, lung, and colorectal cancers, and melanoma....U3-1402 may exert potent antitumor activity in various human cancer cells expressing HER3, and its efficacy is likely to be enriched by HER3 expression.
